{"nctId":"NCT03877510","briefTitle":"Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations","startDateStruct":{"date":"2019-04-03","type":"ACTUAL"},"conditions":["Parkinson Disease"],"count":419,"armGroups":[{"label":"Open Label IPX203","type":"EXPERIMENTAL","interventionNames":["Drug: IPX203"]}],"interventions":[{"name":"IPX203","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Successfully completed Study IPX203-B16-02\n* Able to provide written informed consent prior to the conduct of any study-specific procedures.\n* Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit (Visit 1).\n* Agrees to use a medically acceptable method of contraception throughout the study and for 6 weeks after completing the study.\n\nExclusion Criteria:\n\n* Intends to use any doses of Rytary® or Duopa™ during this study.\n* Plans to use an investigational treatment other than IPX203 during the course of this study.\n* Neurosurgical ablation treatment for PD is planned or anticipated during the study period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study.\n* Participants who, in the opinion of the clinical investigator, should not participate in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events","description":"An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was considered as treatment-emergent if the date of onset was on or after the date of the first open-label study drug administration in this Study IPX203-B16-03 and no later than 1 day after the last study drug dose in the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null}]}]}]},{"type":"SECONDARY","title":"Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":"28.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":"30.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":"28.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":"29.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"16.44"}]}]}]},{"type":"SECONDARY","title":"Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"6.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"6.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"6.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":"6.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"4.56"}]}]}]},{"type":"SECONDARY","title":"Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"7.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"7.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"7.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"8.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"4.81"}]}]}]},{"type":"SECONDARY","title":"Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":"17.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":"17.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":"17.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":"16.79"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"11.29"}]}]}]},{"type":"SECONDARY","title":"Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"2.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"3.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"3.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"3.34"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"2.64"}]}]}]},{"type":"SECONDARY","title":"Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":"23.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":"24.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":"23.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","spread":"22.96"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III","description":"MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"13.66"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Severity (PGI-S)","description":"The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Global Impression of Severity (PGI-S)","description":"The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.07"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PGI-S ≥ 4 and PGI-S ≥ 5","description":"The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression of Severity (CGI-S)","description":"The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression of Severity (CGI-S)","description":"The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a CGI-S ≥ 4 and CGI-S ≥ 5","description":"The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null}]}]}]},{"type":"SECONDARY","title":"39-item Parkinson's Disease Questionnaire (PDQ-39): Total","description":"The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":"27.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":"27.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":"28.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":"29.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PDQ-39: Total","description":"The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"18.65"}]}]}]},{"type":"SECONDARY","title":"Parkinson Anxiety Scale (PAS): Total","description":"The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"8.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"8.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"7.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"8.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Parkinson Anxiety Scale (PAS): Total","description":"The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"6.41"}]}]}]},{"type":"SECONDARY","title":"Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total","description":"The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":"28.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":"28.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.4","spread":"29.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":"30.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total","description":"The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"22.33"}]}]}]},{"type":"SECONDARY","title":"Parkinson's Disease Sleep Scale-2 (PDSS-2) Total","description":"The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"9.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"9.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":"9.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":"9.28"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total","description":"The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"8.92"}]}]}]},{"type":"SECONDARY","title":"Treatment Satisfaction Assessment (TSA)","description":"The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"1.39"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral)","description":"The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":419},"commonTop":["Urinary tract infection","Fall","Dyskinesia","Back pain","Constipation"]}}}